Table 1.
Key components of the recent HBV-related HCC risk stratification systems
| Criteria | mREACH-B | LSM-HCC mCU-HCC | PAGE-B |
|---|---|---|---|
| Age (years) | 30–34: 0 | <51: 0 | 16–29: 0 |
| 35–39: 1 | >50: 10 | 30–39: 2 | |
| 40–44: 2 | 40–49: 4 | ||
| 45–49: 3 | 50–59: 6 | ||
| 50–54: 4 | 60–69: 8 | ||
| 55–59: 5 | ≥70: 1 | ||
| 60–65: 6 | |||
| Gender | Male: 2 | NA | Female: 0 |
| Female: 0 | Male: 6 | ||
| Albumin, g/L | NA | <36: 1 | NA |
| >35: 0 | |||
| Platelets, ×109/L | NA | NA | ≥200,000: 0 100,000–199,999: 6 <100,000: 9 |
| ALT, U/L | <15: 0 15–44: 1 >44: 2 |
NA | NA |
| HBeAg | Positive: 2 | NA | NA |
| Negative: 0 | |||
| DNA | NA | ≤2×105 IU/mL: 0 >2×105 IU/mL: 5 |
NA |
| LS (kPa) | <8: 0 | <8: 0 | NA |
| 8–13: 2 | 8–12: 8 | ||
| >13: 4 | >12: 14 | ||
| Optimal cut offa | 10 | 11 | 17 |
Notes:
a
Optimal cut-off for predicting HCC development in 5 years.
Abbreviations: ALT, alanine transaminase; HBeAg, hepatitis B viral protein; HCC, hepatocellular carcinoma; LS, liver stiffness; LSM, liver stiffness measurement; NA, not applicable; mREACH, modified REACH; mCU-HCC-modified Chinese University-HCC; PAGE-B, platelets, age, gender-HBV.